Gene Expression-Based Assays for Cancers of Unknown Primary

Policy # 00271
Original Effective Date: 10/20/2010
Current Effective Date: 06/12/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider the use of gene expression profiling (GEP), i.e., Tissue of Origin® and CancerTYPE ID® tests, to evaluate the site of origin of a tumor of unknown primary to be eligible for coverage**.

Patient Selection Criteria
Coverage eligibility for the use of gene expression profiling (GEP), i.e., Tissue of Origin® and CancerTYPE ID® tests, to evaluate the site of origin of a tumor of unknown primary will be met when ALL coverage criteria are met:

- Used for tumor for which a single specific site of origin has not been established or resolved by the combination of clinicopathologic studies (immunohistochemistry testing) and consultation with pathologist, radiologist, and oncologist; AND
- Test is used with specimens such as cytology cell blocks or formalin-fixed paraffin embedded tissue; AND
- Requested or similar test was not used before.
When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of Tissue of Origin® and CancerTYPE ID® tests in all other situations, and use of other tests to evaluate the site of origin of a tumor of unknown primary, or to distinguish a primary from a metastatic tumor to be investigational.*

Background/Overview

Cancers of Unknown Primary

Cancers of unknown primary, or occult primary malignancies, are tumors that have metastasized from an unknown primary source; they make up about 3% of all cancers in the United States.

Most cancers of unknown primary are adenocarcinomas or undifferentiated tumors; less commonly, they may be squamous carcinomas, melanoma, soft tissue sarcoma, or neuroendocrine tumors. Osteo- and chondrosarcomas rarely produce cancers of unknown primary. The most common primary sites of cancers of unknown primary are lung and pancreas, followed by colon and stomach, then breast, ovary, prostate, and solid-organ carcinomas of the kidney, thyroid, and liver. Conventional methods used to aid in the identification of the origin of a cancer of unknown primary include a thorough history and physical examination; computed tomography scans of the chest, abdomen, and pelvis; routine laboratory studies; and targeted evaluation of specific signs and symptoms.

Diagnosis and Classification

Cancers of unknown primary can be classified into 4 categories. Adenocarcinomas compose approximately 70% of cancers of unknown primary. Neuroendocrine tumors compose approximately 1%, squamous cell carcinomas 5%, and poorly differentiated cancer 20% to 25% of cancers of unknown primary.

Biopsy of a cancer of unknown primary with detailed pathology evaluation may include immunohistochemical analysis of the tumor. Immunohistochemical analysis identifies different antigens present in different types of tumors and can usually distinguish an epithelial tumor (ie,
Gene Expression-Based Assays for Cancers of Unknown Primary

Policy #  00271
Original Effective Date:  10/20/2010
Current Effective Date:  06/12/2023

carcinoma) from melanoma or sarcoma. Detailed cytokeratin panels often allow further classification of carcinoma; however, tumors of different origins may show overlapping cytokeratin expression. Results of immunohistochemical analysis may provide a narrow differential of possible sources of a tumor’s origin, but not necessarily a definitive answer.

Treatment Selection and Health Outcomes
Treatment is based on the histologic type and clinical features. About 20% of patients with cancer of unknown primary have features that guide treatment. However, about 80% of patients with cancer of unknown primary have a poor prognosis with a survival of 3 to 6 months despite a variety of chemotherapeutic combinations. Multiple sites of involvement are observed in about 50% of patients, commonly in the lungs, liver, bones and lymph nodes. The premise of tissue of origin testing in cancers of unknown primary is that identifying a likely primary tumor site will inform treatment selection leading to improved survival and other outcomes.

Tests Reviewed in This Report
Selected gene expression profiling tests are described in Table 1.

Table 1. Gene Expression Profiling Tests for Cancers of Unknown Primary

<table>
<thead>
<tr>
<th>Test</th>
<th>Manufacturer</th>
<th>Platform</th>
<th>Genes Assayed, n</th>
<th>Tumor Types Assessed, n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tissue of Origina</td>
<td>Cancer Genetics</td>
<td>Oligonucleotide microarray</td>
<td>2000</td>
<td>15</td>
</tr>
<tr>
<td>CancerTYPE ID</td>
<td>Biotheranostics</td>
<td>RT-qPCR</td>
<td>92</td>
<td>54</td>
</tr>
</tbody>
</table>

Adapted from Agwa et al (2013). RT-qPCR: real-time quantitative polymerase chain reaction.
a FormerlyPathWork and ResponseDX: Tissue of Origin.

The Tissue of Origin test is a microarray-based gene expression assay designed to determine the similarity of unknown or unresolved tumors to cancers from 1 of 15 known tumors of origin. The test is intended for tumors for which a single specific site of origin has not been established or resolved by the combination of clinicopathologic studies and consultation with pathologists,
Gene Expression-Based Assays for Cancers of Unknown Primary

Policy #  00271  
Original Effective Date:  10/20/2010  
Current Effective Date:  06/12/2023

radiologists and oncologists. The test should be used with specimens, such as cytology cell blocks, where limited quantity of the specimen precludes standard pathologic workups.

CancerTYPE ID is gene expression profiling by real-time reverse transcription PCR of 92 genes (87 content genes and 5 housekeeping genes) to classify tumors into 28 main cancer types and 50 histological subtypes, utilizing formalin-fixed paraffin embedded tissue, algorithm reported as a probability of a predicted main cancer type and predicted subtype within the main cancer type classification.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

In 2008, the PathWork® Tissue of Origin Test™ (Response Genetics; now Cancer Genetics, Cancer Genetics merged with StemoniX in 2020.) was cleared for marketing with limitations (see below) by the U.S. Food and Drug Administration (FDA) through the 510(k) process (FDA product code: OIW), with subsequent clearances for expanded applications in 2010 and minor modifications in 2012. FDA determined that the test was substantially equivalent to existing tests for use in measuring the degree of similarity between the RNA expression pattern in a patient's fresh-frozen tumor and the RNA expression patterns in a database of tumor samples (poorly differentiated, undifferentiated, metastatic cases) that were diagnosed according to current clinical and histopathologic practice.

Limitations to the clearance were as follows:

- The PathWork Tissue of Origin Test is not intended to establish the origin of tumors that cannot be diagnosed according to current clinical and pathologic practice (eg, a cancer of unknown primary).
- It is not intended to subclassify or modify the classification of tumors that can be diagnosed by current clinical and pathologic practice or to predict disease course, or survival or treatment efficacy, or to distinguish primary from metastatic tumor.
- Tumor types not in the PathWork Tissue of Origin Test database may have RNA expression patterns similar to RNA expression patterns in tumor types in the database, leading to indeterminate results or misclassifications.

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical
Gene Expression-Based Assays for Cancers of Unknown Primary

Policy # 00271
Original Effective Date: 10/20/2010
Current Effective Date: 06/12/2023

Laboratory Improvement Amendments (CLIA). CancerTYPE ID®‡ (Biotheranostics, San Diego, CA) is available under the auspices of the CLIA. Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the FDA has chosen not to require any regulatory review of this test.

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Cancers of unknown primary represent 3% to 4% of cancers diagnosed in the United States. These cancers are heterogeneous and many accompanied by poor prognoses. A detailed history and physical combined with imaging and tissue pathology can identify some, but not all, primary sources of secondary tumors. It is suggested that identifying the likely primary source with gene expression profiling to direct treatment may improve health outcomes.

Summary of Evidence
For individuals who have cancers of unknown primary who receive gene expression profiling, the evidence includes studies of clinical validity, and 2 randomized controlled trials (RCTs) that have evaluated clinical utility. Relevant outcomes are overall survival, disease-specific survival, test validity, and quality of life. Of the 2 commercially available tests reviewed, 1 has been cleared by the U.S. Food and Drug Administration (Tissue of Origin). For these tests, the clinical validity is the ability of a test to determine the site of origin. Using different reference standards (known tumor type, reference diagnosis, a primary tumor identified during follow-up, immunohistochemical analysis) for the tissue of origin, the tests have reported sensitivities or concordances generally high (eg, 80% to 90% or more). However, the reference standard is imperfect, and evidence for clinical validity does not support potential benefit. Direct evidence of clinical utility is provided by studies that compare health outcomes for patients managed with and without the test. The benefit would be most convincingly demonstrated through a trial randomizing patients with cancers of unknown primary to receive treatment based on gene expression profiling results or usual care. One published RCT and 1 conference presentation with this design were identified. These trials did not find a
Gene Expression-Based Assays for Cancers of Unknown Primary

Policy # 00271
Original Effective Date: 10/20/2010
Current Effective Date: 06/12/2023

A survival benefit for patients with cancers of unknown primary who received treatment based on the site of origin as determined by molecular testing. A limitation in interpretation of the published trial results is that there were few treatments that were site specific, so there was minimal difference in the actual treatments given to the 2 groups. In the second RCT, most cancers responded to the control treatments. Therefore, the possibility remains that if more site-specific treatments are developed, molecular testing to determine the site of origin in patients with cancers of unknown primary may have clinical utility, but the absence of convincing evidence from RCTs prevents conclusions about clinical utility. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Supplemental Information
Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in ‘Supplemental Information’ if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

National Comprehensive Cancer Network
Current National Comprehensive Cancer Network (NCCN) guidelines for the workup of an occult primary malignancy (v.1.2022) address the use of molecular methods to classify tumors. Gene sequencing to predict tissue of origin is not recommended (category 2A recommendation [based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate]. The guidelines later note:

“In an attempt to identify the tissue of origin, biopsy specimens are often analyzed by immunohistochemistry (IHC). Gene expression profiling (GEP) assays have also been developed to attempt to identify the tissue of origin in patients with occult primary cancers. Both methodologies offer a similar range of accuracy in tumor classification (approximately 75%). While there may be diagnostic benefit of GEP, a clinical benefit has not been demonstrated.”
Gene Expression- Based Assays for Cancers of Unknown Primary

Policy #  00271
Original Effective Date:  10/20/2010
Current Effective Date:  06/12/2023

National Institute for Health and Care Excellence
A 2010 clinical guidance from the National Institute for Health and Care Excellence recommended against the use of gene expression profiling to identify primary tumors in patients with cancers of unknown primary. This recommendation was based on “limited evidence that gene-expression based profiling changes the management of patients with cancer of unknown primary and no evidence of improvement in outcome.” The guidance included a research recommendation for trials to assess the clinical utility of gene expression profiling.

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
A 2013 technology assessment was commission by Centers for Medicare & Medicaid for consideration by the MEDCAC panel. Studies identified evaluating CancerTYPE ID, miRview, and PathWorkDx through November 2012, were included. The report concluded that all tests had similar accuracies, ranging from 85% to 88% (9 studies of PathWorkDx, 6 of CancerTYPE ID, 4 of MiRview), but that evidence was insufficient to evaluate the effect on management and outcomes. (Following review, the MEDCAC panel voted 2 [scale of 1 = low, 3 = intermediate, and 5 = high confidence] after considering the question: “How confident are you that there is sufficient evidence to determine whether genetic testing of tumor tissue affects health outcomes (including benefits and harms) for patients with cancer whose anticancer treatment strategy is guided by the results of each of the following?”).

Medicare MolDX carriers (Noridian, Novitas, Palmetto, Wisconsin Physician Services, and CGS Administrators) decisions for PathWork Tissue of Unknown Origin Test and Cancer TYPE ID have found them to be “reasonable and necessary”.

Ongoing and Unpublished Clinical Trials
A currently unpublished trial that might influence this review is listed in Table 2.
Gene Expression-Based Assays for Cancers of Unknown Primary

Table 2. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td><strong>A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy (CUPISCO)</strong></td>
<td>790</td>
<td>Jun 2024</td>
</tr>
<tr>
<td>NCT03498521</td>
<td><strong>A Randomised Phase III Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With Carcinoma of an Unknown Primary (CUP)</strong></td>
<td>243</td>
<td>Aug 2019 (Conference Presentation)</td>
</tr>
<tr>
<td>Unpublished</td>
<td><strong>The Value of Tissue-of-origin Profiling in Predicting Primary Site and Directing Therapy in Patients With Cancer of Unknown Primary: a Prospective Randomized Controlled Study</strong></td>
<td>172</td>
<td>March 2021 (status unknown)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

References

Gene Expression-Based Assays for Cancers of Unknown Primary

Policy # 00271
Original Effective Date: 10/20/2010
Current Effective Date: 06/12/2023


©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Gene Expression-Based Assays for Cancers of Unknown Primary

Policy # 00271
Original Effective Date: 10/20/2010
Current Effective Date: 06/12/2023


©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Gene Expression-Based Assays for Cancers of Unknown Primary

Policy # 00271
Original Effective Date: 10/20/2010
Current Effective Date: 06/12/2023


Policy History
Original Effective Date: 10/20/2010
Current Effective Date: 06/12/2023

10/14/2010 Medical Policy Committee review
10/20/2010 Medical Policy Implementation Committee approval.
06/14/2012 Medical Policy Committee review
06/20/2012 Medical Policy Implementation Committee approval. A new test for formalin-fixed paraffin-embedded (FFPE) specimens added to the investigational statement.
01/23/2013 Coding updated
05/02/2013 Medical Policy Committee review
05/22/2013 Medical Policy Implementation Committee approval. Coverage statement changed to be generalizable to gene expression profiling and not specific to the Pathwork test.
05/01/2014 Medical Policy Committee review
05/21/2014 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
05/07/2015 Medical Policy Committee review
05/20/2015 Medical Policy Implementation Committee approval. Title change. Coverage eligibility unchanged.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Gene Expression-Based Assays for Cancers of Unknown Primary

Policy # 00271
Original Effective Date: 10/20/2010
Current Effective Date: 06/12/2023

08/03/2015 Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
01/01/2016 Coding update
02/03/2016 Coding update
05/05/2016 Medical Policy Committee review
05/18/2016 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
05/04/2017 Medical Policy Committee review
05/17/2017 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2018 Coding update
05/03/2018 Medical Policy Committee review
05/16/2018 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/07/2018 Coding update
10/29/2018 Coding update
01/01/2019 Coding update
05/02/2019 Medical Policy Committee review
05/15/2019 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
05/07/2020 Medical Policy Committee review
05/13/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
05/06/2021 Medical Policy Committee review
05/12/2021 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
05/05/2022 Medical Policy Committee review
05/11/2022 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/03/2022 Medical Policy Committee review
11/09/2022 Medical Policy Implementation Committee approval. Added a coverage statement to be eligible for coverage with criteria. Revised the investigational statement.
05/04/2023 Medical Policy Committee review
Gene Expression-Based Assays for Cancers of Unknown Primary

Policy #  00271
Original Effective Date:  10/20/2010
Current Effective Date:  06/12/2023

05/10/2023 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
Next Scheduled Review Date:  05/2024

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2022 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.
Gene Expression-Based Assays for Cancers of Unknown Primary

Policy # 00271
Original Effective Date: 10/20/2010
Current Effective Date: 06/12/2023

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>81406, 81479, 81504, 81540</td>
</tr>
<tr>
<td></td>
<td>Add code effective 06/01/2023: 81599</td>
</tr>
<tr>
<td>HCPCS</td>
<td>No codes</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
   1. Consultation with technology evaluation center(s);
   2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
   3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;

B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
Gene Expression-Based Assays for Cancers of Unknown Primary

Policy #   00271
Original Effective Date:  10/20/2010
Current Effective Date:  06/12/2023

C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease. For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.